Matthew joined Onyx Equities in 2016. He oversees implementation and execution of asset level business plans for the retail and industrial segments of the portfolio.

Prior to joining Onyx, Matthew served as Vice President at The Goldstein Group for 8 years, where he facilitated over $78 million in lease transactions, and represented over one million square feet of commercial space throughout the metro-New York market.

Matthew graduated from the University of Richmond with a Bachelor of Arts in Economics and Political Science. In addition, he is a member of the International Council of Shopping Centers and IOREBA.

Mr. Wolfe is the Co-Managing Partner in the Property Tax Department at Skoloff &

Wolfe, PC, where he focuses his practice on representing taxpayers in significant real estate tax appeals and property tax related matters. He has extensive experience in all types of property tax appeals, including hotel, multi-family, retail, office, and industrial properties. Mr. Wolfe frequently counsels clients on the property tax implications of the development, acquisition, and disposition of significant assets. He also counsels clients with respect to property tax exemptions and PILOT agreements.

Mr. Wolfe serves on the Board of the National Association of Property Tax Attorneys (NAPTA) and as the Co-Chair of the Real Property Tax Practice Committee of the New Jersey State Bar Association. Mr. Wolfe has been featured or quoted in a wide variety of local and national publications, including Forbes.com, GlobeSt.com, Marketwatch.com, The Washington Post, The Wall Street Journal, Law.com, Law360.com, The New York Law Journal, and Commerce Magazine.

Mr. Wolfe has a track record of obtaining significant assessment reductions on behalf

of his clients.

Examples of those assessment reductions include:

• Reduced hotel assessment from $188 million to $131million;

• Reduced multi-family assessment from $116 million to $67 million;

• Reduced office assessment from $115.5 million to $90million;

• Reduced supermarket anchored center from $66.9 million to $46 million;

• Reduced nursing home assessment from $36 million to $10.1million;

• Reduced big box retail assessment from $21.3 million to $13.4 million;

• Reduced office assessment from $27.8 million to $6.5million.

Mr. Wolfe began his career as an associate at the law firm of Davis Polk and

Wardwell in New York. While at Davis Polk, he focused his practice on regulatory

investigations, securities litigation and banking disputes.

Mr. Wolfe is a member of the American Bar Association House of Delegates and is

the Co-Chair of the ABA’s Diversity & Inclusion 360 Presidential Commission. As a

young lawyer, Mr. Wolfe served as the Chair of the ABA Young Lawyers Division, the

ABA’s largest entity with more than 130,000 members.

Mr. Wolfe received his J.D. from New York University School of Law, and graduated

from Cornell University with distinction in all subjects.

Daniel Loughlin is the vice chairman for JLL’s New Jersey office markets group. He provides corporate representation for both the acquisition and disposition of commercial real estate and advisory services for strategic planning and site development with an expertise in the pharmaceutical and biotech industries.

Experience

Dan began his career at JLL in July 2008 due to the merger with

The Staubach Company.

Prior to joining JLL, Dan was a managing principal of The Staubach Company’s New Jersey corporate services division which he joined in 1998. In 1997, Dan was a principal of Loughlin Stanton, LLC, a commercial real estate firm he co-founded.

Notable transactions

· Sanofi – 1.2M SF Campus Sale – Bridgewater, NJ

· Roche - 1.2M SF R&D Campus Sale – Nutley, NJ

· Allergan – 431,500 SF HQ Acquisition – Madison, NJ

· Merck – 1.2M SF Campus Sale – Summit, NJ

· Mallinckrodt – 150,000 SF HQ Acquisition – Bedminster, NJ

· Sanofi – 450,000 SF HQ Acquisition – Bridgewater, NJ

· Linde – 115,634 SF HQ Acquisition – Bridgewater, NJ

· SJP Properties- 330,00 SF Sale-Jersey City, NJ

Education and affiliations

Dan is a graduate of Long Island University C.W. Post. He has earned a CoreNet Master of Corporate Real Estate (MCR) accreditation, a professional designation focused on the strategic management of corporate real estate.

He is a member of the New Jersey Biotechnology Council and a board member for The Cancer Support Community of central New Jersey. He is a 2011 recipient of JLL’s Champion of Excellence award and 2016 MVP Broker Lead.

An architect by training, Sally has a reputation for bringing great creativity, innovation and attention to detail to every project she works on, including some of HDR’s most high-profile education, science, workplace, and mixed-use projects around the globe. In her role as Education & Science leader, she directs and executes regional project leadership, strategic planning and business development efforts to help life science corporations and developers achieve their missions and goals.

Matt Hebert is a project executive and life sciences leader at DPR Construction, specializing in highly complex facilities and multi-phased capital improvement projects. With over 27 years of experience, Matt brings deep expertise in managing technically demanding projects that integrate sophisticated MEP systems, advanced equipment, and critical process piping—the backbone of pharmaceutical, R&D, and clinical research facilities.

Having started his career in healthcare construction, Matt saw firsthand the profound impact of scientific discovery and patient care, reinforcing his commitment to building environments that support life-changing work. He understands the uncompromising quality standards these projects demand to protect sensitive research, maintain clean environments, and ensure regulatory compliance.

Matt is known for fostering strong early engagement with design teams and leveraging alternative delivery methods such as design-assist and design-build. This collaborative approach streamlines decision-making, enhances constructability, and ensures alignment with clients’ business and scientific goals from concept to completion.

As a strategic partner, Matt acts as a crucial bridge between owners, design partners, and trade teams—developing clear execution plans that unite all stakeholders and enable seamless project delivery. A certified NYC DOB Site Safety Manager, he maintains an unwavering commitment to safety and quality throughout every phase.

Matt holds a Bachelor of Science degree in Civil Engineering from Bucknell University.

John Falcone is a business development manager in the life sciences for Siemens industry, specializing in bridging advanced technologies with real-world laboratory needs. With expertise in engineering, controls, and facility operations, he has supported high-level biosafety projects, guided and complex lab retrofits. Known for his relationship-driven approach and technical insight, John helps organizations strengthen research infrastructure, improve operational safety, and achieve lasting results while fostering collaboration and innovation across the scientific community.

Bill Hunter is Managing Director at Perceptive Real Estate Equities, Inc. With more than two decades of experience as a life sciences and healthcare real estate investor, developer and operator, his career spans a period dating back to when institutional life sciences real estate was still emerging as a distinct asset class. His career spans acquisitions, leasing, development, and asset repositioning across major US life sciences markets, with involvement in more than $10.5 billion of acquisitions, 12.4 million square feet of leasing, and 4.6 million square feet of campus repositioning projects in Boston, the Mid Atlantic, Research Triangle Park, San Francisco, San Diego, and Miami. Bill was a pre-IPO hire at BioMed Realty Trust and an early team member at Wexford Science and Technology, where he helped build two of the platforms that shaped the modern life sciences real estate market. His experience spans the full life cycle of laboratory, GMP, clinical, and R & D environments, including technical infrastructure, regulatory requirements, and the operational needs of pharmaceutical, bio technology, medical device, CDMO, and university research users. More recently, Bill has focused on complex and dislocated situations, supporting owners, lenders, and investors in navigating stalled projects, capital structure challenges, and asset repositioning decisions, with an emphasis on restoring stability and long-term optionality.